Discover
CTNM
Contineum Therapeutics, Inc.
15.24
2 x 11.59
2 x 19.57
bid
ask
-
1.15
7.02%
2 @ 04:00 PM
15.23 -0.01 (0.07%)
| Ytd | 33.33% | |
| 1y | 295.84% |
15.14
day range
16.39
3.72
52 week range
16.91
| Open | 16.37 | Prev Close | 16.39 | Low | 15.14 | High | 16.39 | Mkt Cap | 569.77M |
| Vol | 313.50K | Avg Vol | 302.67K | EPS | -1.94 | P/E | N/A | Forward P/E | -7.68 |
| Beta | N/A | Short Ratio | 13.66 | Inst. Own | 72.39% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-05 | 50-d Avg | 13.14 | 200-d Avg | 12.59 | 1yr Est | 29.25 |
CTNM News
gurufocus.com
Contineum Therapeutics Publishes Discovery of Potential Best-in-Class LPAR1 Antagonist PIPE-791 in J
Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmace
benzinga.com
Contineum Therapeutics Publishes 'Discovery of PIPE-791, a Potent and Brain-Penetrant Lysophosphatid
- Manuscript describes the discovery of LPAR1 antagonist PIPE-791, now in a Phase 2 clinical trial f
businesswire.com
Contineum Therapeutics Publishes Discovery of Potential Best-in-Class LPAR1 Antagonist PIPE-791 in J
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company),